TESAMORELIN
Price range: $50.00 through $75.00
SSL Secured
Secure Checkout
Guaranteed Delivery
Third-Party Tested
Buy Tesamorelin 10mg – GHRH Analog Research Peptide
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) – the hypothalamic peptide responsible for stimulating pituitary GH secretion. With a trans-3-hexenoic acid modification at its N-terminus that improves its stability, Tesamorelin is currently the highest-evidence GHRH analog available for research, having received FDA approval as Egrifta in 2010 for HIV-associated lipodystrophy treatment. This FDA approval – the only therapeutic approval for any GHRH analog – provides an unusually robust clinical evidence base for Tesamorelin’s GHRH receptor mechanism compared to other GH secretagogue research compounds.
Available in 10mg lyophilized format, independently tested to greater than 99% purity. All products are for laboratory research use only. Our research-grade Tesamorelin is not Egrifta – it is not a pharmaceutical product and is not approved for any human use.
Mechanism & Clinical Evidence Base
Tesamorelin acts at GHRH receptors on pituitary somatotroph cells, stimulating pulsatile GH release through the same mechanism as endogenous GHRH. The trans-3-hexenoic acid N-terminal modification protects against dipeptidyl peptidase IV (DPP-IV) degradation – extending its research utility compared to native GHRH while preserving physiological pulsatile GH stimulation.
Target: GHRH receptor (GHRHR) on pituitary somatotroph cells
GH profile: Stimulates pulsatile GH release – preserving physiological GH pulse dynamics
IGF-1 downstream: GHRH, GH, hepatic IGF-1 production
Clinical validation: Phase 3 trials supporting GHRH receptor mechanism (FDA approved 2010 as Egrifta)
Product Specifications
| Compound | Tesamorelin |
| Also Known As | TESA, TH9507, Egrifta (pharmaceutical trade name) |
| Type | Synthetic analog of human GHRH (Growth Hormone-Releasing Hormone) |
| Class | GHRH Receptor Agonist |
| CAS Number | 218949-48-5 |
| Molecular Formula | C221H356N66O75S |
| Molecular Weight | 5,136.7 g/mol |
| Amino Acids | 44 amino acids (full-length GHRH + N-terminal trans-3-hexenoic acid modification) |
| Form | Lyophilized powder |
| Purity | >99% HPLC Verified - Batch COA Available |
| Available Size | 10mg, 20mg |
| Clinical Background | FDA-approved as Egrifta for HIV-associated lipodystrophy (2010) |
| Storage | Lyophilized: -20°C | Reconstituted: 2-8°C, use within 28 days |
| Reconstitution | Bacteriostatic Water (BAC Water) |
| Intended Use | Research Use Only (RUO) - Not the pharmaceutical product Egrifta |
Frequently Ask Questions
